Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|19|29|5177-5192

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.19, Iss.29, 2013-01, pp. : 5177-5192

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Does Non-Alcoholic Fatty Liver Disease (NAFLD) Increase Cardiovascular Risk?

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 8, Iss. 4, 2008-12 ,pp. : 301-307

Bentham Science Publishers

Access to resources Recommend Favorite

Methodologies for Investigating Natural Medicines for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)

By  

Current Pharmaceutical Biotechnology, Vol. 13, Iss. 2, 2012-02 ,pp. : 278-291

Bentham Science Publishers

Access to resources Recommend Favorite

Nonalcoholic Fatty Liver Disease and Cardiovascular Disease

By  

Current Pharmaceutical Design, Vol. 20, Iss. 14, 2014-04 ,pp. : 2403-2411

Bentham Science Publishers

Access to resources Recommend Favorite

Current Treatment Strategies for Non-Alcoholic Fatty Liver Disease (NAFLD)

By  

Current Drug Discovery Technologies, Vol. 4, Iss. 2, 2007-08 ,pp. : 133-140

Bentham Science Publishers

Access to resources Recommend Favorite

Redox Homeostasis and Epigenetics in Non-alcoholic Fatty Liver Disease (NAFLD)

By  

Current Pharmaceutical Design, Vol. 19, Iss. 15, 2013-03 ,pp. : 2737-2746

Bentham Science Publishers

Access to resources Recommend Favorite